Eczema
Supporting the internal factors associated with eczema — skin barrier integrity, immune balance and healthy inflammatory response.
The biological basis of eczema — and how internal support fits alongside treatment.
Eczema (atopic dermatitis) is influenced by both surface events and internal biological function. While emollients and prescription treatments act primarily at the skin’s surface, the features that drive eczema are governed by underlying biology — a compromised skin barrier that loses moisture too easily, an over-reactive immune response, and inflammatory signalling that contributes to itch and flares.
Dermatology literature describes eczema as a chronic, relapsing condition in which barrier dysfunction and immune activity reinforce one another. Internal factors are increasingly discussed as part of the picture — inflammatory and immune balance, micronutrient status relevant to barrier repair, and antioxidant defence — together shaping the internal environment in which the skin maintains its barrier and manages inflammation.
The Eczema formulation is designed to support the internal cofactors these processes depend on — providing a consistent internal foundation that sits alongside a patient’s topical or prescribed treatment, not in place of it.
What’s in the Eczema formulation — and why
This formulation represents the standard base composition for eczema-prone skin, designed for general clinical use and practitioner-led recommendation.
Each active is included at a defined dose for its documented role in a pathway relevant to eczema. Where evidence is limited, associative or based on a different route or dose, this is reflected in the wording — a key advantage of pharmacist compounding over standardised manufactured supplements.
| Ingredient | Primary pathway relevance | Mechanism | Evidence summary | Key reference |
|---|---|---|---|---|
| Vitamin A1000 IU | Epithelial & immune function | Supports epithelial integrity and immune function | Serum and skin retinol are lower in atopic dermatitis; vitamin A supports the epithelial integrity and immune function that underlie barrier health | Chakraborti G et al. Indian Journal of Dermatology. 2018;63(3):251–254 |
| Vitamin E100 IU | Antioxidant defence | Lipid-soluble antioxidant protecting cell membranes from oxidative damage | A randomised controlled trial reported improvement in atopic dermatitis with oral vitamin E supplementation | Faghihi G et al. Journal of Research in Medical Sciences. 2015;20(11):1053–1057 |
| Vitamin B12 (cyanocobalamin)0.25 mg | Normal cell metabolism | Supports DNA synthesis and normal cell division | Vitamin B12 has been studied in eczema and supports DNA synthesis and normal cell metabolism; included as a nutritional cofactor | NIH Office of Dietary Supplements. Vitamin B12 Fact Sheet. |
| Zinc picolinate50 mg (elemental zinc ~10 mg) | Barrier repair; immune function | Supports immune function, protein synthesis and normal wound healing | Zinc supports immune function, protein synthesis and normal wound repair — all relevant to barrier recovery | Dhaliwal S et al. American Journal of Clinical Dermatology. 2020;21(1):21–39 |
| Vitamin D3 (cholecalciferol)1000 IU | Immune regulation; barrier support | Influences immune responses and epidermal barrier biology | A 2024 meta-analysis of randomised trials found vitamin D reduced atopic dermatitis severity | Nielsen AY et al. Nutrients. 2024;16(23):4128 |
| Palmitoylethanolamide (PEA)300 mg | Itch & inflammatory signalling | Endogenous lipid mediator influencing mast-cell and sensory pathways | PEA modulates mast-cell and sensory pathways involved in itch; a large clinical study of PEA in eczema reported symptomatic benefit | Eberlein B et al. Journal of the European Academy of Dermatology and Venereology. 2008;22(1):73–82 |
References describe the pathway and supporting evidence relevant to each ingredient. This formulation supports the biological processes associated with eczema and is not intended to diagnose, treat, cure or prevent the condition.
Pharmaceutical-grade precision. Every ingredient has a purpose.
The Eczema formulation is compounded by licensed Australian pharmacists within established TGA regulatory frameworks, using pharmaceutical-grade raw materials selected for documented roles in immune regulation, barrier support and inflammatory balance.
The compounding approachTwo contexts, one formulation
The Eczema formulation is designed to support skin from within as part of a patient’s daily routine. For patients managing recurrent flares and sensitivity, it provides a consistent internal foundation targeting immune and inflammatory balance and the factors associated with barrier repair.
Topical and prescription eczema therapies act on the skin’s surface and local barrier and inflammatory processes. This formulation supports the internal resources — immune balance, micronutrient status and antioxidant defence — that sit beneath those surface processes, complementing existing treatment rather than replacing it.
Ready to order the Eczema formulation for your clinic?
All formulations are compounded fresh to order and shipped directly to your clinic.